Ipilimumab/IDD-1 combination vaccine (Medarex/IDM)

N/A

Report date: 2022/02/17 17:14:44

Base Information

Drug NameIpilimumab/IDD-1 combination vaccine (Medarex/IDM)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProstate-specific antigen modulators
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Prostate-specific antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Clinical)
Highest Status in ChinaN/A
Originator CompaniesIdm PharmaMedarex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIdm PharmaMedarex Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A